Case Study: Fortune 500 Pharmaceutical Company protects patient data and accelerates drug discovery with Okera

Okera Enables Fortune 500 Pharmaceutical Company to Protect Patients’ Data During Drug Discovery

The Fortune 500 Pharmaceutical Company, a global biopharmaceutical firm, needed a faster and more secure way to give researchers access to decades of clinical trial data while protecting patients’ protected health information (PHI). Before working with Okera, the company relied on manual access controls, custom dataset copies, and AWS IAM roles that were difficult to scale across its Amazon S3 data lake and analytics environment.

Okera implemented its Active Data Access Platform (ODAP) to provide unified, fine-grained access control across tools and data sources, with dynamic masking, tokenization, and automated policy enforcement at the column, row, and cell level. With Okera, the company improved secure data access, streamlined compliance with GDPR, CCPA, and HIPAA, and accelerated drug discovery with immediate policy application across its analytics ecosystem.